Yvonne Linney

Board Member at Bionano Genomics, Inc. Principal at Linney BioConsulting.

📍 Saratoga, California, United States🔄 Updated September 2026💼 1 investments📅 10 years investing🗓 Last invested Jan 2016𝕏 @upgrade_to_unlock
Angel investor🌍 United States
1
Total investments
0
Early stage
1
Mid stage
0
Late stage
10y
Years active

Portfolio

1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
2016
Founded in 2012, Transcriptic has developed the first robotic cloud lab platform for on-demand life science research. It’s powered by the Transcriptic Common Lab Environment (TCLE) a scalable, digital infrastructure that integrates laboratory processes, instruments and IoT technologies into a single user interface. Researchers can carry out scalable, reproducible and rapid experimentation from anywhere in the world. Top ten pharmaceutical companies, as well as emerging biotech companies, are using the platform to gain more reproducibility and flexibility in the design and control of their experiments. By leveraging cloud-based technologies, users can access the power of a fully automated laboratory – whether in their own labs through an on-premise deployment of TCLE or through Transcriptic’s Bioassays services – all through a simple web-based interface. Transcriptic is transforming drug discovery and synthetic biology research by helping scientists focus on accelerating discoveries instead of labor-intensive bench work.
mid stageBiotechnology
Experience · 1 entries
All (1)
Investments (1)
Board (1)
2016
Board Member
2016
Founded in 2012, Transcriptic has developed the first robotic cloud lab platform for on-demand life science research. It’s powered by the Transcriptic Common Lab Environment (TCLE) a scalable, digital infrastructure that integrates laboratory processes, instruments and IoT technologies into a single user interface. Researchers can carry out scalable, reproducible and rapid experimentation from anywhere in the world. Top ten pharmaceutical companies, as well as emerging biotech companies, are using the platform to gain more reproducibility and flexibility in the design and control of their experiments. By leveraging cloud-based technologies, users can access the power of a fully automated laboratory – whether in their own labs through an on-premise deployment of TCLE or through Transcriptic’s Bioassays services – all through a simple web-based interface. Transcriptic is transforming drug discovery and synthetic biology research by helping scientists focus on accelerating discoveries instead of labor-intensive bench work.
mid stageBiotechnology